Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study
To describe the experience of treatment with baricitinib (BARI) and/or tocilizumab (TCZ), in monotherapy or combined, in patients admitted for interstitial pneumonia secondary to COVID19, and for 30 days after discharge. Medical records of patients admitted with COVID19 and IP with PaO2/FiO2 70 años...
Gespeichert in:
| Veröffentlicht in: | Reumatología clinica 2022-03, Vol.18 (3), p.150-156 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 156 |
|---|---|
| container_issue | 3 |
| container_start_page | 150 |
| container_title | Reumatología clinica |
| container_volume | 18 |
| creator | Rosas, José Liaño, Francisco Pasquau Cantó, Mónica Llombart Barea, José María Carrasco Beser, Amparo Raga Rabasa, José Tomás Algado Adsuar, Francisco Martínez Auli, Brian Vila López, Isabel Fernández Sainz, Ana María Garijo Ramis, Pere Esquerdo Pérez, Laura Ruiz Rebollo, Mª Luisa Navarrete Lorido, Raquel Hernández Escolar, Laura Gómez |
| description | To describe the experience of treatment with baricitinib (BARI) and/or tocilizumab (TCZ), in monotherapy or combined, in patients admitted for interstitial pneumonia secondary to COVID19, and for 30 days after discharge.
Medical records of patients admitted with COVID19 and IP with PaO2/FiO2 70 años); 11 (18%) de ellos en los primeros 15 días del ingreso y cuatro (7%) entre los días 16 y 30. Veintitrés (38%) pacientes recibieron BARI, 12 (52%) en monoterapia (Grupo 1), durante seis (DE: 2.6) días de promedio, ninguno de ellos in |
| doi_str_mv | 10.1016/j.reuma.2020.10.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7699160</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1699258X20302710</els_id><sourcerecordid>2473410489</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3749-f0962dc4f0611e5f6e71576a1c8ab5c4d12b71b459c183883bf3f9cb2ea6e5003</originalsourceid><addsrcrecordid>eNp9Ud1u0zAUthCIdYMnQEK-5IIUO47zgwTS6AZUGtrENsad5dgn1FViF9upKM_EQ-KsY4Ibriwdf3_nfAg9o2ROCS1frecexkHOc5JPkzkhzQM0y2nFMl4V7CGa0bJpspzXXw_QYQhrQjjP6_oxOmCM8ZqVdIZ-nf7YgDdgFeAbE1c4rgBfB8Cuw--kN8pEY02LpdX4yinTm5_Js8WfnHUJ6uVmh53HCze0xoJ-iY3FFzImwRj2gksbwYeYdGSPL2yK7KyR-BKUs1r6HY4u0b2zcmv8GPDi_MvyhDav8TH-DLLPbpzvNb6Mo949QY862Qd4evceoev3p1eLj9nZ-Yfl4vgsU6wqmqwjTZlrVXSkpBR4V0JFeVVKqmrZclVomrcVbQveKFqzumZtx7pGtTnIEjgh7Ai93etuxnYArdIyXvZi482QAgsnjfj3x5qV-Oa2okoHp-Uk8OJOwLvvI4QoBhMU9L204MYg8qJiBSVF3SQo20OVdyF46O5tKBFTz2ItbnsWU8_TMPWcWM__TnjP-VNsArzZAyDdaWvAi6BuW9bGg4pCO_Nfg98ddL3W</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473410489</pqid></control><display><type>article</type><title>Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study</title><source>Elsevier ScienceDirect Journals</source><source>Alma/SFX Local Collection</source><creator>Rosas, José ; Liaño, Francisco Pasquau ; Cantó, Mónica Llombart ; Barea, José María Carrasco ; Beser, Amparo Raga ; Rabasa, José Tomás Algado ; Adsuar, Francisco Martínez ; Auli, Brian Vila ; López, Isabel Fernández ; Sainz, Ana María Garijo ; Ramis, Pere Esquerdo ; Pérez, Laura Ruiz ; Rebollo, Mª Luisa Navarrete ; Lorido, Raquel Hernández ; Escolar, Laura Gómez</creator><creatorcontrib>Rosas, José ; Liaño, Francisco Pasquau ; Cantó, Mónica Llombart ; Barea, José María Carrasco ; Beser, Amparo Raga ; Rabasa, José Tomás Algado ; Adsuar, Francisco Martínez ; Auli, Brian Vila ; López, Isabel Fernández ; Sainz, Ana María Garijo ; Ramis, Pere Esquerdo ; Pérez, Laura Ruiz ; Rebollo, Mª Luisa Navarrete ; Lorido, Raquel Hernández ; Escolar, Laura Gómez ; COVID19-HMB Group</creatorcontrib><description><![CDATA[To describe the experience of treatment with baricitinib (BARI) and/or tocilizumab (TCZ), in monotherapy or combined, in patients admitted for interstitial pneumonia secondary to COVID19, and for 30 days after discharge.
Medical records of patients admitted with COVID19 and IP with PaO2/FiO2<300, treated with BARI and/or TCZ, and compared with patients who did not, were retrospectively reviewed.
Sixty patients were included; 43 (72%) are males, mean age 67 (SD: 14) years (<50 years: 17%; 51–70: 30%; >70: 53%), with 8.5 (SD: 1) days of symptoms. Sixteen (27%) patients required ICU (94% in <70 years). Fifteen (25%) patients died, 67% in >70 years; 11 (18%) patients died in the first 15 days of admission and 4 (7%) between days 16 to 30. Twenty-three (38%) patients received BARI, 12 (52%) monotherapy (Group 1), during 6 (SD: 2.6) days on average, none required ICU and 2 (17%) died. Thirty-one (52%) patients received TCZ, 20 (33%) as monotherapy (Group 2), 16 (52%) patients required ICU and 4 (20%) died. In the 11 (18%) patients who received BARI (2.8 [SD: 2.5] days average) and TCZ combined (Group 3), 3 (27%) required ICU and died. There were no severe side effects in BARI or TCZ patients. In the 17 (28%) patients who received neither BARI nor TCZ (Group 4), none required ICU and 6 (35%) died. Mean (SD) PaO2/FiO2 at admission between groups was respectively: 167 (82.3), 221 (114.9), 236 (82.3), 276 (83.2).
Treatment with BARI and TCZ did not cause serious side effects. They could be considered early in patients with NI secondary to COVID19 and impaired PaO2/PaFi.
Describir la experiencia con baricitinib (BARI) y/o tocilizumab (TCZ), en monoterapia o combinados en pacientes ingresados por neumonía intersticial (NI) por COVID-19 y durante los 30 días después del alta.
Se revisaron retrospectivamente las historias clínicas de los pacientes ingresados por COVID-19 y NI, con PaO2/FiO2<300, tratados con BARI y/o TCZ y se compararon con pacientes que no los recibieron.
Se incluyeron 60 pacientes; 43 (72%) varones, edad media 67 (DE: 14) años (< 50 años: 17%; 51-70: 30%; > 70: 53%), y 8,5 (DE: 1) días de síntomas. Dieciséis (27%) ingresaron en la unidad de cuidados intensivos (UCI) (94% < 70 años). Quince (25%) fallecieron (67% > 70 años); 11 (18%) de ellos en los primeros 15 días del ingreso y cuatro (7%) entre los días 16 y 30. Veintitrés (38%) pacientes recibieron BARI, 12 (52%) en monoterapia (Grupo 1), durante seis (DE: 2.6) días de promedio, ninguno de ellos ingresó en UCI y dos (17%) fallecieron. Treinta y un (52%) pacientes recibieron una dosis de TCZ, 20 (33%) en monoterapia (Grupo 2), 16 (52%) ingresaron en UCI y cuatro (20%) fallecieron. Entre los 11 (18%) pacientes que recibieron BARI (2,8 [DE: 2,5] días de promedio) y TCZ combinados (Grupo 3), tres (27%) ingresaron en UCI y fallecieron. No hubo efectos secundarios graves entre los que recibieron BARI y/o TCZ. Entre los 17 (28%) pacientes que no recibieron ni BARI ni TCZ (Grupo 4), ninguno ingresó en UCI y seis (35%) fallecieron. La PaO2/FiO2 media (DE) al ingreso entre los grupos fue respectivamente: 167 (82,3), 221 (114,9), 236 (82,3), 276 (83,2).
El tratamiento con BARI y TCZ no provocó efectos secundarios graves. Podrían considerarse precozmente en pacientes con NI secundaria a COVID-19 y deterioro de PaO2/PaFi.]]></description><identifier>ISSN: 1699-258X</identifier><identifier>EISSN: 2173-5743</identifier><identifier>EISSN: 1885-1398</identifier><identifier>DOI: 10.1016/j.reuma.2020.10.009</identifier><identifier>PMID: 33358361</identifier><language>eng</language><publisher>Spain: Elsevier España, S.L.U</publisher><subject>Baricitinib ; COVID-19 ; COVID19 ; ICU ; Interstitial pneumonia ; Neumonía intersticial ; Original ; Tocilizumab ; UCI</subject><ispartof>Reumatología clinica, 2022-03, Vol.18 (3), p.150-156</ispartof><rights>2022 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología</rights><rights>Copyright © 2020. Publicado por Elsevier España, S.L.U.</rights><rights>2022 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved. 2022 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3749-f0962dc4f0611e5f6e71576a1c8ab5c4d12b71b459c183883bf3f9cb2ea6e5003</citedby><cites>FETCH-LOGICAL-c3749-f0962dc4f0611e5f6e71576a1c8ab5c4d12b71b459c183883bf3f9cb2ea6e5003</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1699258X20302710$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33358361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rosas, José</creatorcontrib><creatorcontrib>Liaño, Francisco Pasquau</creatorcontrib><creatorcontrib>Cantó, Mónica Llombart</creatorcontrib><creatorcontrib>Barea, José María Carrasco</creatorcontrib><creatorcontrib>Beser, Amparo Raga</creatorcontrib><creatorcontrib>Rabasa, José Tomás Algado</creatorcontrib><creatorcontrib>Adsuar, Francisco Martínez</creatorcontrib><creatorcontrib>Auli, Brian Vila</creatorcontrib><creatorcontrib>López, Isabel Fernández</creatorcontrib><creatorcontrib>Sainz, Ana María Garijo</creatorcontrib><creatorcontrib>Ramis, Pere Esquerdo</creatorcontrib><creatorcontrib>Pérez, Laura Ruiz</creatorcontrib><creatorcontrib>Rebollo, Mª Luisa Navarrete</creatorcontrib><creatorcontrib>Lorido, Raquel Hernández</creatorcontrib><creatorcontrib>Escolar, Laura Gómez</creatorcontrib><creatorcontrib>COVID19-HMB Group</creatorcontrib><title>Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study</title><title>Reumatología clinica</title><addtitle>Reumatol Clin (Engl Ed)</addtitle><description><![CDATA[To describe the experience of treatment with baricitinib (BARI) and/or tocilizumab (TCZ), in monotherapy or combined, in patients admitted for interstitial pneumonia secondary to COVID19, and for 30 days after discharge.
Medical records of patients admitted with COVID19 and IP with PaO2/FiO2<300, treated with BARI and/or TCZ, and compared with patients who did not, were retrospectively reviewed.
Sixty patients were included; 43 (72%) are males, mean age 67 (SD: 14) years (<50 years: 17%; 51–70: 30%; >70: 53%), with 8.5 (SD: 1) days of symptoms. Sixteen (27%) patients required ICU (94% in <70 years). Fifteen (25%) patients died, 67% in >70 years; 11 (18%) patients died in the first 15 days of admission and 4 (7%) between days 16 to 30. Twenty-three (38%) patients received BARI, 12 (52%) monotherapy (Group 1), during 6 (SD: 2.6) days on average, none required ICU and 2 (17%) died. Thirty-one (52%) patients received TCZ, 20 (33%) as monotherapy (Group 2), 16 (52%) patients required ICU and 4 (20%) died. In the 11 (18%) patients who received BARI (2.8 [SD: 2.5] days average) and TCZ combined (Group 3), 3 (27%) required ICU and died. There were no severe side effects in BARI or TCZ patients. In the 17 (28%) patients who received neither BARI nor TCZ (Group 4), none required ICU and 6 (35%) died. Mean (SD) PaO2/FiO2 at admission between groups was respectively: 167 (82.3), 221 (114.9), 236 (82.3), 276 (83.2).
Treatment with BARI and TCZ did not cause serious side effects. They could be considered early in patients with NI secondary to COVID19 and impaired PaO2/PaFi.
Describir la experiencia con baricitinib (BARI) y/o tocilizumab (TCZ), en monoterapia o combinados en pacientes ingresados por neumonía intersticial (NI) por COVID-19 y durante los 30 días después del alta.
Se revisaron retrospectivamente las historias clínicas de los pacientes ingresados por COVID-19 y NI, con PaO2/FiO2<300, tratados con BARI y/o TCZ y se compararon con pacientes que no los recibieron.
Se incluyeron 60 pacientes; 43 (72%) varones, edad media 67 (DE: 14) años (< 50 años: 17%; 51-70: 30%; > 70: 53%), y 8,5 (DE: 1) días de síntomas. Dieciséis (27%) ingresaron en la unidad de cuidados intensivos (UCI) (94% < 70 años). Quince (25%) fallecieron (67% > 70 años); 11 (18%) de ellos en los primeros 15 días del ingreso y cuatro (7%) entre los días 16 y 30. Veintitrés (38%) pacientes recibieron BARI, 12 (52%) en monoterapia (Grupo 1), durante seis (DE: 2.6) días de promedio, ninguno de ellos ingresó en UCI y dos (17%) fallecieron. Treinta y un (52%) pacientes recibieron una dosis de TCZ, 20 (33%) en monoterapia (Grupo 2), 16 (52%) ingresaron en UCI y cuatro (20%) fallecieron. Entre los 11 (18%) pacientes que recibieron BARI (2,8 [DE: 2,5] días de promedio) y TCZ combinados (Grupo 3), tres (27%) ingresaron en UCI y fallecieron. No hubo efectos secundarios graves entre los que recibieron BARI y/o TCZ. Entre los 17 (28%) pacientes que no recibieron ni BARI ni TCZ (Grupo 4), ninguno ingresó en UCI y seis (35%) fallecieron. La PaO2/FiO2 media (DE) al ingreso entre los grupos fue respectivamente: 167 (82,3), 221 (114,9), 236 (82,3), 276 (83,2).
El tratamiento con BARI y TCZ no provocó efectos secundarios graves. Podrían considerarse precozmente en pacientes con NI secundaria a COVID-19 y deterioro de PaO2/PaFi.]]></description><subject>Baricitinib</subject><subject>COVID-19</subject><subject>COVID19</subject><subject>ICU</subject><subject>Interstitial pneumonia</subject><subject>Neumonía intersticial</subject><subject>Original</subject><subject>Tocilizumab</subject><subject>UCI</subject><issn>1699-258X</issn><issn>2173-5743</issn><issn>1885-1398</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9Ud1u0zAUthCIdYMnQEK-5IIUO47zgwTS6AZUGtrENsad5dgn1FViF9upKM_EQ-KsY4Ibriwdf3_nfAg9o2ROCS1frecexkHOc5JPkzkhzQM0y2nFMl4V7CGa0bJpspzXXw_QYQhrQjjP6_oxOmCM8ZqVdIZ-nf7YgDdgFeAbE1c4rgBfB8Cuw--kN8pEY02LpdX4yinTm5_Js8WfnHUJ6uVmh53HCze0xoJ-iY3FFzImwRj2gksbwYeYdGSPL2yK7KyR-BKUs1r6HY4u0b2zcmv8GPDi_MvyhDav8TH-DLLPbpzvNb6Mo949QY862Qd4evceoev3p1eLj9nZ-Yfl4vgsU6wqmqwjTZlrVXSkpBR4V0JFeVVKqmrZclVomrcVbQveKFqzumZtx7pGtTnIEjgh7Ai93etuxnYArdIyXvZi482QAgsnjfj3x5qV-Oa2okoHp-Uk8OJOwLvvI4QoBhMU9L204MYg8qJiBSVF3SQo20OVdyF46O5tKBFTz2ItbnsWU8_TMPWcWM__TnjP-VNsArzZAyDdaWvAi6BuW9bGg4pCO_Nfg98ddL3W</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Rosas, José</creator><creator>Liaño, Francisco Pasquau</creator><creator>Cantó, Mónica Llombart</creator><creator>Barea, José María Carrasco</creator><creator>Beser, Amparo Raga</creator><creator>Rabasa, José Tomás Algado</creator><creator>Adsuar, Francisco Martínez</creator><creator>Auli, Brian Vila</creator><creator>López, Isabel Fernández</creator><creator>Sainz, Ana María Garijo</creator><creator>Ramis, Pere Esquerdo</creator><creator>Pérez, Laura Ruiz</creator><creator>Rebollo, Mª Luisa Navarrete</creator><creator>Lorido, Raquel Hernández</creator><creator>Escolar, Laura Gómez</creator><general>Elsevier España, S.L.U</general><general>Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220301</creationdate><title>Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study</title><author>Rosas, José ; Liaño, Francisco Pasquau ; Cantó, Mónica Llombart ; Barea, José María Carrasco ; Beser, Amparo Raga ; Rabasa, José Tomás Algado ; Adsuar, Francisco Martínez ; Auli, Brian Vila ; López, Isabel Fernández ; Sainz, Ana María Garijo ; Ramis, Pere Esquerdo ; Pérez, Laura Ruiz ; Rebollo, Mª Luisa Navarrete ; Lorido, Raquel Hernández ; Escolar, Laura Gómez</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3749-f0962dc4f0611e5f6e71576a1c8ab5c4d12b71b459c183883bf3f9cb2ea6e5003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Baricitinib</topic><topic>COVID-19</topic><topic>COVID19</topic><topic>ICU</topic><topic>Interstitial pneumonia</topic><topic>Neumonía intersticial</topic><topic>Original</topic><topic>Tocilizumab</topic><topic>UCI</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rosas, José</creatorcontrib><creatorcontrib>Liaño, Francisco Pasquau</creatorcontrib><creatorcontrib>Cantó, Mónica Llombart</creatorcontrib><creatorcontrib>Barea, José María Carrasco</creatorcontrib><creatorcontrib>Beser, Amparo Raga</creatorcontrib><creatorcontrib>Rabasa, José Tomás Algado</creatorcontrib><creatorcontrib>Adsuar, Francisco Martínez</creatorcontrib><creatorcontrib>Auli, Brian Vila</creatorcontrib><creatorcontrib>López, Isabel Fernández</creatorcontrib><creatorcontrib>Sainz, Ana María Garijo</creatorcontrib><creatorcontrib>Ramis, Pere Esquerdo</creatorcontrib><creatorcontrib>Pérez, Laura Ruiz</creatorcontrib><creatorcontrib>Rebollo, Mª Luisa Navarrete</creatorcontrib><creatorcontrib>Lorido, Raquel Hernández</creatorcontrib><creatorcontrib>Escolar, Laura Gómez</creatorcontrib><creatorcontrib>COVID19-HMB Group</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Reumatología clinica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rosas, José</au><au>Liaño, Francisco Pasquau</au><au>Cantó, Mónica Llombart</au><au>Barea, José María Carrasco</au><au>Beser, Amparo Raga</au><au>Rabasa, José Tomás Algado</au><au>Adsuar, Francisco Martínez</au><au>Auli, Brian Vila</au><au>López, Isabel Fernández</au><au>Sainz, Ana María Garijo</au><au>Ramis, Pere Esquerdo</au><au>Pérez, Laura Ruiz</au><au>Rebollo, Mª Luisa Navarrete</au><au>Lorido, Raquel Hernández</au><au>Escolar, Laura Gómez</au><aucorp>COVID19-HMB Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study</atitle><jtitle>Reumatología clinica</jtitle><addtitle>Reumatol Clin (Engl Ed)</addtitle><date>2022-03-01</date><risdate>2022</risdate><volume>18</volume><issue>3</issue><spage>150</spage><epage>156</epage><pages>150-156</pages><issn>1699-258X</issn><eissn>2173-5743</eissn><eissn>1885-1398</eissn><abstract><![CDATA[To describe the experience of treatment with baricitinib (BARI) and/or tocilizumab (TCZ), in monotherapy or combined, in patients admitted for interstitial pneumonia secondary to COVID19, and for 30 days after discharge.
Medical records of patients admitted with COVID19 and IP with PaO2/FiO2<300, treated with BARI and/or TCZ, and compared with patients who did not, were retrospectively reviewed.
Sixty patients were included; 43 (72%) are males, mean age 67 (SD: 14) years (<50 years: 17%; 51–70: 30%; >70: 53%), with 8.5 (SD: 1) days of symptoms. Sixteen (27%) patients required ICU (94% in <70 years). Fifteen (25%) patients died, 67% in >70 years; 11 (18%) patients died in the first 15 days of admission and 4 (7%) between days 16 to 30. Twenty-three (38%) patients received BARI, 12 (52%) monotherapy (Group 1), during 6 (SD: 2.6) days on average, none required ICU and 2 (17%) died. Thirty-one (52%) patients received TCZ, 20 (33%) as monotherapy (Group 2), 16 (52%) patients required ICU and 4 (20%) died. In the 11 (18%) patients who received BARI (2.8 [SD: 2.5] days average) and TCZ combined (Group 3), 3 (27%) required ICU and died. There were no severe side effects in BARI or TCZ patients. In the 17 (28%) patients who received neither BARI nor TCZ (Group 4), none required ICU and 6 (35%) died. Mean (SD) PaO2/FiO2 at admission between groups was respectively: 167 (82.3), 221 (114.9), 236 (82.3), 276 (83.2).
Treatment with BARI and TCZ did not cause serious side effects. They could be considered early in patients with NI secondary to COVID19 and impaired PaO2/PaFi.
Describir la experiencia con baricitinib (BARI) y/o tocilizumab (TCZ), en monoterapia o combinados en pacientes ingresados por neumonía intersticial (NI) por COVID-19 y durante los 30 días después del alta.
Se revisaron retrospectivamente las historias clínicas de los pacientes ingresados por COVID-19 y NI, con PaO2/FiO2<300, tratados con BARI y/o TCZ y se compararon con pacientes que no los recibieron.
Se incluyeron 60 pacientes; 43 (72%) varones, edad media 67 (DE: 14) años (< 50 años: 17%; 51-70: 30%; > 70: 53%), y 8,5 (DE: 1) días de síntomas. Dieciséis (27%) ingresaron en la unidad de cuidados intensivos (UCI) (94% < 70 años). Quince (25%) fallecieron (67% > 70 años); 11 (18%) de ellos en los primeros 15 días del ingreso y cuatro (7%) entre los días 16 y 30. Veintitrés (38%) pacientes recibieron BARI, 12 (52%) en monoterapia (Grupo 1), durante seis (DE: 2.6) días de promedio, ninguno de ellos ingresó en UCI y dos (17%) fallecieron. Treinta y un (52%) pacientes recibieron una dosis de TCZ, 20 (33%) en monoterapia (Grupo 2), 16 (52%) ingresaron en UCI y cuatro (20%) fallecieron. Entre los 11 (18%) pacientes que recibieron BARI (2,8 [DE: 2,5] días de promedio) y TCZ combinados (Grupo 3), tres (27%) ingresaron en UCI y fallecieron. No hubo efectos secundarios graves entre los que recibieron BARI y/o TCZ. Entre los 17 (28%) pacientes que no recibieron ni BARI ni TCZ (Grupo 4), ninguno ingresó en UCI y seis (35%) fallecieron. La PaO2/FiO2 media (DE) al ingreso entre los grupos fue respectivamente: 167 (82,3), 221 (114,9), 236 (82,3), 276 (83,2).
El tratamiento con BARI y TCZ no provocó efectos secundarios graves. Podrían considerarse precozmente en pacientes con NI secundaria a COVID-19 y deterioro de PaO2/PaFi.]]></abstract><cop>Spain</cop><pub>Elsevier España, S.L.U</pub><pmid>33358361</pmid><doi>10.1016/j.reuma.2020.10.009</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1699-258X |
| ispartof | Reumatología clinica, 2022-03, Vol.18 (3), p.150-156 |
| issn | 1699-258X 2173-5743 1885-1398 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7699160 |
| source | Elsevier ScienceDirect Journals; Alma/SFX Local Collection |
| subjects | Baricitinib COVID-19 COVID19 ICU Interstitial pneumonia Neumonía intersticial Original Tocilizumab UCI |
| title | Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T21%3A22%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Experience%20With%20the%20Use%20of%20Baricitinib%20and%20Tocilizumab%20Monotherapy%20or%20Combined,%20in%20Patients%20With%20Interstitial%20Pneumonia%20Secondary%20to%20Coronavirus%20COVID19:%20A%20Real-World%20Study&rft.jtitle=Reumatolog%C3%ADa%20clinica&rft.au=Rosas,%20Jos%C3%A9&rft.aucorp=COVID19-HMB%20Group&rft.date=2022-03-01&rft.volume=18&rft.issue=3&rft.spage=150&rft.epage=156&rft.pages=150-156&rft.issn=1699-258X&rft.eissn=2173-5743&rft_id=info:doi/10.1016/j.reuma.2020.10.009&rft_dat=%3Cproquest_pubme%3E2473410489%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2473410489&rft_id=info:pmid/33358361&rft_els_id=S1699258X20302710&rfr_iscdi=true |